Decoding the Role of ALDOB K87 Lactylation in Pulmonary Hypertension

Study Background and Research Question

Pulmonary hypertension (PH) is a progressive and often fatal cardiopulmonary disorder, marked by pulmonary vascular remodeling, occlusive arteriopathy, and eventual right ventricular failure. Despite advances in vasodilator therapies, long-term outcomes remain poor, with five-year survival rates below 65% (source: paper). The molecular mechanisms driving the aberrant proliferation and phenotypic switching of pulmonary artery smooth muscle cells (PASMCs)—central contributors to vascular remodeling—are incompletely understood. Recent research has illuminated the importance of metabolic reprogramming, particularly the shift from oxidative phosphorylation to aerobic glycolysis (Warburg effect), in fueling pathological PASMC behaviors. However, the linkage between metabolic byproducts, such as lactate, and the epigenetic and post-translational modifications that drive disease progression in PH remained elusive until now.

Key Innovation from the Reference Study

The pivotal innovation of Yi et al. (2026) lies in the identification of ALDOB (aldolase B) K87 lactylation as a master regulator of mitochondrial fission and metabolic reprogramming in PH (source: paper). The study moves beyond the well-characterized role of histone lactylation, focusing instead on nonhistone protein modification and its downstream impact on cellular metabolism and structure. By integrating lactylome-wide profiling with mechanistic validation, the authors establish a novel lactate–ALDOB–dynamin-related protein 1 (DRP1) axis, bridging metabolic flux with mitochondrial dynamics and smooth muscle cell proliferation in the context of PH.

Methods and Experimental Design Insights

To dissect the molecular underpinnings of PH, the authors employed a multi-layered approach combining in vitro and in vivo models:

• Lactylomic profiling: Quantitative mass spectrometry was used to identify and quantify protein lactylation events in hypoxia-induced human PASMCs and rodent PH models.
• Site-specific mutagenesis: ALDOB mutants were engineered to mimic or prevent K87 lactylation, enabling direct assessment of functional consequences.
• Mitochondrial dynamics assays: Imaging and biochemical assays measured mitochondrial fission, DRP1 recruitment, and downstream metabolic changes.
• Genetic and pharmacologic modulation: Both genetic knockdown and pharmacological inhibition of ALDOB lactylation were tested for their impact on PASMC proliferation and PH progression in animal models.
• Validation of signaling pathways: The role of SIRT1 as an ALDOB delactylase was assessed, as was the involvement of the sentrin/SUMO-specific peptidase 3 (SENP3)–mediated deSUMOylation of DRP1.

These experimental strategies enabled precise dissection of the causative chain linking metabolic reprogramming, post-translational modification, and cellular remodeling in PH.

Core Findings and Why They Matter

The study’s major discoveries include:

• ALDOB K87 lactylation is markedly elevated in hypoxic PASMCs and rodent PH models, correlating with increased glycolytic flux and lactate production (source: paper).
• Lactate-driven ALDOB K87 lactylation facilitates the recruitment of DRP1 to mitochondria via SENP3-mediated deSUMOylation, promoting mitochondrial fission—a process critical for PASMC proliferation and migration.
• Disruption of ALDOB lactylation (by genetic or pharmacologic means) attenuates mitochondrial fission and reverses pathological PASMC behaviors in vitro and in vivo, highlighting the modification as a functional driver of disease.
• SIRT1 functions as a delactylase, and its downregulation in PH sustains pathogenic ALDOB lactylation, further linking metabolic state to disease progression.

These findings establish a self-reinforcing pathological circuit—whereby hypoxia and glycolytic shift drive lactate production, which in turn potentiates ALDOB K87 lactylation and mitochondrial fragmentation, supporting the proliferative and migratory phenotype of PASMCs that underpins vascular remodeling in PH.

Protocol Parameters

• cell proliferation assay | ED50 < 2 ng/ml | murine BALB/c 3T3 cells, PASMCs | Quantifies PDGF-BB mitogen activity for in vitro studies and models relevant to vascular remodeling | product_spec
• mitochondrial fission assay | variable (imaging, DRP1 localization) | PASMCs, murine/rodent PH models | Measures DRP1-driven mitochondrial fragmentation, essential for validating ALDOB–DRP1 axis | paper
• lactylome sequencing | proteomic profiling (quantitative MS) | PASMCs under hypoxia | Identifies site-specific lactylation events, including ALDOB K87 | paper
• hypoxic exposure | 1–3% O₂, 24–72 h | PASMCs | Mimics disease-relevant microenvironment to induce metabolic and phenotypic changes | workflow_recommendation

Comparison with Existing Internal Articles

Several internal resources complement the mechanistic insights of this study:

• The article "ALDOB K87 Lactylation Drives Mitochondrial Fission in PH" provides a concise summary of the lactate–ALDOB–DRP1 axis, reinforcing the central role of metabolic-epigenetic coupling in vascular remodeling.
• "Murine Recombinant PDGF-BB: Advanced Assay Design & Mitochondrial Insights" bridges cell proliferation assays with mitochondrial investigations, outlining how recombinant PDGF-BB can be leveraged to interrogate smooth muscle cell proliferation and metabolic reprogramming.
• "Optimizing Cell Proliferation Assays with Murine Recombinant PDGF-BB" details best practices for robust cell proliferation assays, a key readout in the current study’s workflow.

Collectively, these resources contextualize the experimental strategies and help researchers design assays that integrate metabolic and proliferative endpoints relevant to PH and vascular remodeling.

Limitations and Transferability

Despite its robust design, the study has several limitations. First, while rodent models and primary PASMCs offer disease relevance, cross-species differences may influence the exact regulation and impact of ALDOB K87 lactylation. Second, the lactylome is dynamic and may intersect with additional post-translational modifications that were not exhaustively characterized. Third, the direct applicability of these findings to human PH patients—particularly regarding therapeutic inhibition of ALDOB lactylation—requires further validation in clinical samples. Nevertheless, the methodology and mechanistic insights are broadly transferable to studies of smooth muscle cell proliferation, mitochondrial dynamics, and metabolic-epigenetic coupling in vascular disease contexts.

Research Support Resources

For researchers aiming to model PASMC proliferation and mitochondrial dynamics, PDGF-BB, murine recombinant protein (SKU P1048; APExBIO) offers a validated tool for stimulating mitogen-dependent proliferation and metabolic remodeling in vitro (product_spec). Its well-characterized activity and compatibility with cell proliferation assays (workflow_recommendation) make it suitable for experimental designs paralleling those in the reference study. As always, protocol optimization should be guided by assay-specific controls and the latest mechanistic evidence.